MIGRAINES

Migraines are the most common type of headache seen in clinical practice and the leading cause of disabling, recurring headache pain, often affecting the whole body with symptoms like intense head pain, sensitivity to light, sound, and smells, nausea, vomiting, and fatigue.

Diagram of the human brain highlighting areas involved in migraine, with numbered labels and explanatory text describing triggers, vascular inflammation, peripheral sensitization, and central sensitization.

How does Botox work?

OnabotulinumToxin A works by targeting the sensory nerve endings and inhibiting the release of neurotransmitters CGRP and Substance P and by down regulating the expression of cell surface receptor TRPV1.

This net effect of OnabotulinumToxin A is that it prevents and reverses sensitization in nociceptive sensory neurons and therefore may indirectly prevent central sensitization and reduced pain

Diagram illustrating the mechanism of action of OnabotulinumtoxinA in chronic migraine, showing peripheral and central nervous system pathways, sensoryization, and neural impulses.

How effective is Botox for Migraines?

As seen in clinical trials, more than 70% of migraine suffers reduced their headache days by 50% after the 3rd treatment cycle.

A chart illustrating that onabotulinumtoxinA reduces the number of headache days in patients with chronic migraine through three treatment cycles, with 70.9% responding after three cycles. The chart includes a pie chart showing the cumulative proportion of responders with a 50% or greater reduction in headache days after three cycles and text highlighting key statistics and notes.
Graph showing significant response rate improvements in patients taking OnabotulinumtoxinA compared to placebo at week 24 for headache and migraine days in two studies.

The PREEMPT clinical trial showed that there is continued reduction in headache days past 52 weeks with continued treatment

Line graph showing the effect of onabotulinumtoxinA versus placebo on the frequency of headache days over 56 weeks. The graph indicates a greater reduction in headache days with onabotulinumtoxinA, especially during the open-label phase, with statistical significance at week 24 and week 56.